Atossa Therapeutics (ATOS) Stock Forecast, Price Target & Predictions
ATOS Stock Forecast
Atossa Therapeutics stock forecast is as follows: an average price target of $5.00 (represents a 400.00% upside from ATOS’s last price of $1.00) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ATOS Price Target
The average price target for Atossa Therapeutics (ATOS) is $5.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 400.00% upside from ATOS's last price of $1.00.
ATOS Analyst Ratings
According to 3 Wall Street analysts, Atossa Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ATOS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Atossa Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 08, 2023 | Louise Chen | Cantor Fitzgerald | $5.00 | $0.83 | 499.81% | 400.00% |
The latest Atossa Therapeutics stock forecast, released on Sep 08, 2023 by Louise Chen from Cantor Fitzgerald, set a price target of $5.00, which represents a 499.81% increase from the stock price at the time of the forecast ($0.83), and a 400.00% increase from ATOS last price ($1.00).
Atossa Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.00 | $1.00 | $1.00 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Atossa Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atossa Therapeutics's last price of $1.00. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Ascendiant | Buy | Buy | Hold |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 08, 2023 | Cantor Fitzgerald | Overweight | Initialise |
Atossa Therapeutics's last stock rating was published by Ascendiant on Sep 11, 2024. The company gave ATOS a "Buy" rating, the same as its previous rate.
Atossa Therapeutics Financial Forecast
Atossa Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $24.12K | $182.67K |
| Avg Forecast | - | - | - | - | - | - | - | $22.00K | $128.57K |
| High Forecast | - | - | - | - | - | - | - | $26.40K | $154.28K |
| Low Forecast | - | - | - | - | - | - | - | $17.60K | $102.86K |
| # Analysts | - | - | - | - | - | - | - | 9 | 8 |
| Surprise % | - | - | - | - | - | - | - | 1.10% | 1.42% |
Atossa Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. ATOS's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $24.12K (Mar 14).
Atossa Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 9 | 8 |
| EBITDA | - | - | - | - | - | - | - | $-2.29M | $-1.84M |
| Avg Forecast | - | - | - | - | - | - | - | $-2.49M | $-1.11M |
| High Forecast | - | - | - | - | - | - | - | $-1.99M | $-884.39K |
| Low Forecast | - | - | - | - | - | - | - | $-2.99M | $-1.33M |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 1.67% |
undefined analysts predict ATOS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atossa Therapeutics's previous annual EBITDA (undefined) of $NaN.
Atossa Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 9 | 8 |
| Net Income | - | - | - | - | - | - | - | $-2.41M | $-1.94M |
| Avg Forecast | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.54M | $-2.63M | $-1.16M |
| High Forecast | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.54M | $-2.10M | $-931.89K |
| Low Forecast | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.55M | $-7.54M | $-3.16M | $-1.40M |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 1.67% |
Atossa Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATOS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Atossa Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 9 | 8 |
| SG&A | - | - | - | - | - | - | - | $2.01M | $1.84M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Atossa Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ATOS last annual SG&A of $2.01M (Mar 14).
Atossa Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 9 | 8 |
| EPS | - | - | - | - | - | - | - | $-17.78 | $-26.04 |
| Avg Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-21.60 | $-10.80 |
| High Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-17.28 | $-8.64 |
| Low Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-25.92 | $-12.96 |
| Surprise % | - | - | - | - | - | - | - | 0.82% | 2.41% |
According to undefined Wall Street analysts, Atossa Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATOS previous annual EPS of $NaN (undefined).
Atossa Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| OCGN | Ocugen | $0.83 | $5.00 | 502.41% | Buy |
| ATOS | Atossa Therapeutics | $1.04 | $5.00 | 380.77% | Buy |
| INO | Inovio Pharmaceuticals | $1.96 | $8.00 | 308.16% | Buy |
| VXRT | Vaxart | $0.59 | $2.00 | 238.98% | Hold |
| NVAX | Novavax | $9.00 | $20.33 | 125.89% | Buy |
| GOVX | GeoVax Labs | $2.27 | $4.00 | 76.21% | Buy |
| PALI | Palisade Bio | $1.90 | $1.50 | -21.05% | Buy |